Mibefradil: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(3 intermediate revisions by 2 users not shown)
Line 1: Line 1:
{{CMG}},{{SS}}
{{Drugbox
{{Drugbox
| Verifiedfields = changed
| Verifiedfields = changed
Line 19: Line 15:


<!--Pharmacokinetic data-->
<!--Pharmacokinetic data-->
| bioavailability =
| bioavailability = 70 %
| metabolism =
| protein_bound = > 99 %
| elimination_half-life =   
| metabolism = [[Hepatic]]
| elimination_half-life =  17-25 h
| excretion =   
| excretion =   


Line 52: Line 49:
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey      = HBNPJJILLOYFJU-VMPREFPWSA-N
| StdInChIKey      = HBNPJJILLOYFJU-VMPREFPWSA-N
| melting_point = 128
| melting_notes = (dihydrochloride salt)
}}
}}
__NOTOC__
{{SI}}
{{CMG}}
==Overview==
'''Mibefradil''' ('''Posicor''') is a drug for the treatment of [[hypertension]] and chronic [[angina pectoris]].  It belongs to a group known as [[calcium channel blockers]].


'''Mibefradil''' ('''Posicor''') is a drug for the treatment of [[hypertension]] and chronic [[angina pectoris]].  It belongs to a group known as [[calcium channel blockers]].
It is nonselective.<ref name="pmid7565636">{{cite journal |author=Bezprozvanny I, Tsien RW |title=Voltage-dependent blockade of diverse types of voltage-gated Ca2+ channels expressed in Xenopus oocytes by the Ca2+ channel antagonist mibefradil (Ro 40-5967) |journal=Mol. Pharmacol. |volume=48 |issue=3 |pages=540–9 |date=September 1995 |pmid=7565636 |doi= |url=http://molpharm.aspetjournals.org/cgi/pmidlookup?view=long&pmid=7565636}}</ref>
It is nonselective.<ref name="pmid7565636">{{cite journal |author=Bezprozvanny I, Tsien RW |title=Voltage-dependent blockade of diverse types of voltage-gated Ca2+ channels expressed in Xenopus oocytes by the Ca2+ channel antagonist mibefradil (Ro 40-5967) |journal=Mol. Pharmacol. |volume=48 |issue=3 |pages=540–9 |date=September 1995 |pmid=7565636 |doi= |url=http://molpharm.aspetjournals.org/cgi/pmidlookup?view=long&pmid=7565636}}</ref>
On June 8, 1998, [[Hoffmann–La Roche|Roche]] announced the voluntary withdrawal of the drug from the market, one year after approval by the FDA, due to the potential for drug interactions, some of them deadly, which may occur when it is taken together with some other medications. <ref>Heart Drug Withdrawn as Evidence Shows It Could Be Lethal: http://www.nytimes.com/1998/06/09/us/heart-drug-withdrawn-as-evidence-shows-it-could-be-lethal.html </ref>
On June 8, 1998, [[Hoffmann–La Roche|Roche]] announced the voluntary withdrawal of the drug from the market, one year after approval by the FDA, due to the potential for drug interactions, some of them deadly, which may occur when it is taken together with some other medications. <ref>Heart Drug Withdrawn as Evidence Shows It Could Be Lethal: http://www.nytimes.com/1998/06/09/us/heart-drug-withdrawn-as-evidence-shows-it-could-be-lethal.html </ref>
==Synthesis==
[[File:Mibefradil1.png|thumb|600px|center|Mibefradil synthesis]]


==References==
==References==
{{Reflist|2}}


{{Reflist}}
{{Membrane transport modulators}}
{{Membrane transport modulators}}


[[Category:Calcium channel blockers]][[Category:Withdrawn drugs]][[Category:Benzimidazoles]][[Category:Organofluorides]][[Category:Ethers]][[Category:Amines]][[Category:Methyl esters]]
[[Category:Calcium channel blockers]]
 
[[Category:Withdrawn drugs]]
[[Category: Other selective calcium channel blockers with mainly vascular effects]][[Category: Dihydropyridine derivatives]][[Category: Cardiovascular Drugs]][[Category: Drug]]
[[Category:Benzimidazoles]]
[[Category:Organofluorides]]
[[Category:Ethers]]
[[Category:Amines]]
[[Category:Drug]]

Latest revision as of 19:24, 8 April 2015

Mibefradil
Clinical data
AHFS/Drugs.comMicromedex Detailed Consumer Information
MedlinePlusa607007
Routes of
administration
Oral
ATC code
Legal status
Legal status
  • Withdrawn from market
Pharmacokinetic data
Bioavailability70 %
Protein binding> 99 %
MetabolismHepatic
Elimination half-life17-25 h
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC29H38FN3O3
Molar mass495.63 g/mol
3D model (JSmol)
Melting point128 °C (262.4 °F) (dihydrochloride salt)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Mibefradil

Articles

Most recent articles on Mibefradil

Most cited articles on Mibefradil

Review articles on Mibefradil

Articles on Mibefradil in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Mibefradil

Images of Mibefradil

Photos of Mibefradil

Podcasts & MP3s on Mibefradil

Videos on Mibefradil

Evidence Based Medicine

Cochrane Collaboration on Mibefradil

Bandolier on Mibefradil

TRIP on Mibefradil

Clinical Trials

Ongoing Trials on Mibefradil at Clinical Trials.gov

Trial results on Mibefradil

Clinical Trials on Mibefradil at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Mibefradil

NICE Guidance on Mibefradil

NHS PRODIGY Guidance

FDA on Mibefradil

CDC on Mibefradil

Books

Books on Mibefradil

News

Mibefradil in the news

Be alerted to news on Mibefradil

News trends on Mibefradil

Commentary

Blogs on Mibefradil

Definitions

Definitions of Mibefradil

Patient Resources / Community

Patient resources on Mibefradil

Discussion groups on Mibefradil

Patient Handouts on Mibefradil

Directions to Hospitals Treating Mibefradil

Risk calculators and risk factors for Mibefradil

Healthcare Provider Resources

Symptoms of Mibefradil

Causes & Risk Factors for Mibefradil

Diagnostic studies for Mibefradil

Treatment of Mibefradil

Continuing Medical Education (CME)

CME Programs on Mibefradil

International

Mibefradil en Espanol

Mibefradil en Francais

Business

Mibefradil in the Marketplace

Patents on Mibefradil

Experimental / Informatics

List of terms related to Mibefradil

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Mibefradil (Posicor) is a drug for the treatment of hypertension and chronic angina pectoris. It belongs to a group known as calcium channel blockers.

It is nonselective.[1]

On June 8, 1998, Roche announced the voluntary withdrawal of the drug from the market, one year after approval by the FDA, due to the potential for drug interactions, some of them deadly, which may occur when it is taken together with some other medications. [2]

Synthesis

Mibefradil synthesis

References

  1. Bezprozvanny I, Tsien RW (September 1995). "Voltage-dependent blockade of diverse types of voltage-gated Ca2+ channels expressed in Xenopus oocytes by the Ca2+ channel antagonist mibefradil (Ro 40-5967)". Mol. Pharmacol. 48 (3): 540–9. PMID 7565636.
  2. Heart Drug Withdrawn as Evidence Shows It Could Be Lethal: http://www.nytimes.com/1998/06/09/us/heart-drug-withdrawn-as-evidence-shows-it-could-be-lethal.html

Template:Membrane transport modulators